On November 6, 2022, Foster Biologics announced the signing of a strategic cooperation agreement with Cytiva at the 5th China International Import Expo Enterprise, which will promote the standardization and scale up of local biologics CDMO services.
Dr. Charlie Zhang, CEO of Foster Biologics, and Ms. Lihua Yu, General Manager of Cytiva Greater China, attended the signing ceremony.
Foster Biologics Co. Ltd. (hereinafter referred to as "Foster Biologics") is an international CDMO company focusing on the process development and large-scale manufacturing of biologics, with core customers and continuous innovation capabilities. Foster Biologics has the CMC technology platform, manufacturing and registration experience in all stages of the complete research and development life-cycle of biologics, and can undertake domestic large-scale manufacturing of overseas License-in projects and overseas commercialization of domestic antibody projects from clinical stage to commercialization, and provide customized commercial manufacturing for strategic partners.
As of October 2022, there are 31 Client's Projects undertaken by Foster Biologics platform, including 3 clinical phase III and commercialization projects, 12 clinical phase I and II projects, 10 dual reporting IND projects in China and US, 20+ process development and pilot manufacturing projects, 2 License-in projects in Europe and US, and 100+ cell line development projects.
In terms of capacity building, Foster Biologics will continue to increase CDMO capacity to achieve the dual core response in East China and North China: 2,000 L capacity in Beijing manufacturing base has obtained the Manufacture License of Pharmaceutical Products issued by NMPA; Hangzhou manufacturing base is expected to increase capacity by 6,000 L in Q2 2024; and the total capacity will reach 38,000 L in Q4 2024. With our highly integrated industrialization technology platform and cGMP manufacturing capacity, we will create opportunities to undertake high-end commercialization projects through large-scale CDMO capacity expansion and provide customers with cost-controlled biologic drugs that meet international quality standards.
The strategic cooperation between Foster Biologics and Cytiva will provide access to single use bioreactors and chromatography systems of different scales from 200 L to 2,000 L, which will accelerate the preclinical process development, clinical filing, early clinical sample manufacturing and commercialization of biologics such as monoclonal antibodies, and will greatly promote the standardization and scale of the local biologics CDMO services, and provide an opportunity for overseas licensing and commercialization. This initiative will greatly promote the standardization and scale of the local biologics CDMO services, and escort the domestic large-scale manufacturing of overseas License-in projects and the clinical to commercialization of domestic antibody drug projects to the sea.
Left: Foster Biologics Business Development Director Yang Bai Middle: Foster Biologics CEO Dr. Xinfeng Zhang Right: Cytiva Industrial Account Manager Weilin Li
